Introduction
In mammals, the kelch family of proteins containing the N-terminal BTB/POZ domain have diverse functions.
The kelch-related superfamily of proteins contain two major structural elements: a BTB/POZ domain in the N-terminus and kelch repeats in the carboxyl terminus (Angel et al., 1988; Adams et al., 2000; Avraham et al., 2002) . The BTB domain is primarily expressed in several zinc-finger-containing transcription factors, and defines a newly characterized protein-protein interaction interface, involved in organizing higher order structures such as chromatin folding or cytoskeleton organization (DiBello et al., 1991; Godt et al., 1993; Xue and Cooley, 1993; Giniger et al., 1994; Robinson et al., 1994; Deweindt et al., 1995; Gerasimova et al., 1995; Hu et al., 1995; Kaplan and Calame, 1997; Kobayashi et al., 2000) . In addition, the biological function of the BTB domain in development, homeostasis, neoplasia and transcription repression has been reported (Ye et al., 1993) . Recent studies of the BTB domain in PLZF (Chen et al., 1993; Dong et al., 1996; Li et al., 1997) , BCL-6 (Seyfert et al., 1996) , GAGA transcription factor, ZF5, Bach2 and PLZF-RAR indicated that this domain is essential for dimerization and transcriptional repression as well as transcriptional activation (von Bulow et al., 1995; Grignani et al., 1998; Guidez et al., 1998; Lin et al., 1998; Reuter et al., 1998) . Keap1 was shown to sequester the Nrf2 transcription factor (NF-E2-related factor 2) in the cytoplasm (Ito et al., 1994; Dinkova-Kostova et al., 2002) . This interaction was downregulated in the presence of electrophilic agents that stimulate the translocation of Nrf2 to the nucleus, initiating a cytoprotective electrophilic counterattack response. The BTB proteins were also shown to be substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3 (Xu et al., 2003) .
The kelch repeats are important for the maintenance of the ordered cytoskeleton and have been demonstrated in calicin, a-scruin and gigaxonin (Sanders et al., 1996; Bomont et al., 2000) . Although the exact function of these 'kelch' repeat proteins has not been fully identified, biochemical and mutational analyses provide strong evidence that they function in multiprotein complexes through contact sites in their b-propeller domain (Bork and Doolittle, 1994; Ito et al., 1994) . At least 61 kelchrelated proteins have been identified in various organisms, but their physiological and biochemical functions remain largely uncharacterized.
Several lines of evidence suggest that the kelch repeats constitute an actin-binding site: (1) each of the two kelch repeat domains of Limulus a-scruin was shown to bind to actin in vitro (Owen and DeRosier, 1993; Schmid et al., 1994; Way et al., 1995) ; (2) defects in some proteins carrying kelch repeats, such as Drosophila Kelch or Caenorhabditis elegans SPE-26, are known to affect the subcellular localization of cytoskeletal actin (Robinson et al., 1994; Varkey et al., 1995) ; (3) mutation in the kelch repeats in human gigaxonin was reported to be a pathological target in giant axonal neuropathy (Bomont et al., 2000) ; and (4) mutations in the neuronal nuclear matrix protein NRPB/ENC1 were observed in brain tumors (Kim et al., 1998; Liang et al., 2004) . More recently, however, it has been suggested that the kelch repeats may also bind to proteins other than actin. For instance, Physarum actin-fragmin kinase specifically phosphorylates actin molecules that are complexed with fragmin, suggesting that this kinase is likely to recognize molecular features of both actin and fragmin (Eichinger et al., 1996) . In addition, Limulus b-scruin and bovine calicin are known to be localized in a subcellular region that retains no obvious structure involving actin, implying that they may interact with different target proteins (von Bulow et al., 1995; Way et al., 1995) . Recent studies have shown that hDKUR, a human homolog of the kelch protein, is involved in a ring-like structure (Mai et al., 2004) . Thus, the kelch repeats appear to bind to a wider range of proteins than previously expected (Ohmachi et al., 1999) .
Mayven was identified in our laboratory as an actinbinding protein predominantly expressed in brain (Soltysik-Espanola et al., 1999) . Interestingly, Mayven contains an SH3-binding motif (PPXPPX) in the Nterminus, and a BTB/POZ domain-like structure and 'kelch repeats' in the C-terminal domain. The human Mayven shares 63% identity (77% similarity) with the Drosophila ring canal ('kelch') protein. The BTB/POZ domain of Mayven can self-dimerize in vitro (Soltysik-Espanola et al., 1999) , which might be important for its interaction with other BTB/POZ-containing proteins. In U373-MG astrocytoma/glioblastoma cells, Mayven colocalized with actin filaments in stress fibers and in patchy, cortical actin-rich regions of the cell margins. In primary rat hippocampal neurons, Mayven is associated with actin through the 'kelch' repeats within the C-terminus of Mayven. Mayven also functions as an actin-binding protein that may be redistributed along axonal processes and might be involved in the dynamic organization of the actin cytoskeleton in brain cells (Soltysik-Espanola et al., 1999) . However, whether Mayven has additional functions independent of its ability to bind actin is unknown. Therefore, we decided to examine Mayven-mediated effects on breast epithelial cells.
AP-1 (activating protein 1) is a sequence-specific transcription factor composed of homodimers or heterodimers of the Jun family (c-Jun, Jun D and Jun B) or heterodimers of the Jun family members with any of the Fos family members (c-Fos, Fos B, Fra1 and Fra2) (see review by Eferl and Wagner, 2003) . AP-1 both activates and represses transcription through a cisacting element in the promoter region of target genes, and has long been associated with proliferation. AP-1 directs the expression of a critical target gene or genes, such as the cyclin D1 gene, in response to cytokines, stress and mitogenic signals (Shaulian and Karin, 2001) . The promoter for cyclin D1 contains an AP-1 site, and ectopic expression of c-Jun induces cyclin D1 mRNA expression (Fu et al., 2004b) . Cyclin D1 expression and the activity of cyclin D1 reporters are under complex regulation and are markedly influenced by AP-1 and beta-catenin/TCF signaling pathways. Thus, AP-1 transcription factors are key regulatory molecules that play a central role in controlling cell proliferation and transformation by converting mitogen-activated protein kinase (MAPK) signals into the expression of specific target genes.
Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1-S phase of the cell cycle (Fu et al., 2004a) . Amplification or overexpression of cyclin D1 plays a pivotal role in the development of a subset of human cancers including breast cancer (Wang et al., 2004) . Cyclin D1 associates with and regulates the activity of transcription factors, coactivators and corepressors that govern histone acetylation and chromatin remodeling proteins.
The subunits and regulators of the AP-1 complex have been implicated in breast cancer biology, therapeutic response and prognosis (Eferl and Wagner, 2003; Liu et al., 2004; Milde-Langosch et al., 2004) . Increased c-Jun activation was observed in human breast cancer, and elevated AP-1 signaling affects the breast cancer phenotype. AP-1 activity is associated with cell proliferation and neoplastic transformation (Shah et al., 2002) . Activation of c-Jun in mammary epithelial cells resulted in a loss of epithelial polarity, disruption of intercellular junctions and normal barrier function and the formation of irregular multilayers. Overexpression of c-Jun in MCF-7 breast cancer cells resulted in a variety of phenotype changes related to the increased motility and invasion of MCF-7 breast cancer cells (Daschner et al., 1999; Johnston et al., 1999; Milde-Langosch et al., 2000) .
In this study, we have investigated the function of Mayven and its BTB/POZ domain. We observed specific induction of c-Jun by Mayven, which enhanced cyclin D1 promoter activity and cyclin D1 protein expression in breast cancer cells.
Results

Expression and localization of Mayven
To investigate the pattern of Mayven expression, Mayven levels were analysed by Northern blot analysis in several human breast cancer cell lines. Mayven was found to be expressed abundantly in these breast cancer cell lines ( Figure 1 ). We further examined the expression level of Mayven in human primary breast tissues and human breast tumors by immunohistochemistry. Mayven expression in breast cancer tumors was abundant and was found to be broad and diffuse (Figure 2c and d) , while its expression level in normal breast tissue was low and was detected in the basal layer of the mammary ducts ( Figure  2a and b). A similar pattern of Mayven expression in additional breast tumors (15 samples) and normal breast epithelial cells (five samples) was observed (data not shown). Thus, these results show that Mayven is overexpressed in breast cancer.
Mayven-induced c-Jun overexpression
To identify genes that are regulated by Mayven, we applied cDNA microarray technology to profile changes in gene expression associated with Mayven expression. Total mRNA was prepared from MCF-7 cells transfected with either green fluorescent protein (GFP)-Mayven or control GFP-vector, and was analysed for gene expression using microarrays that contain 1200 human genes. After normalization, 24 of 1200 (2.0%) genes examined by gene array analysis were differentially expressed in the GFP-Mayven-transfected cells as compared to the GFP-vector-transfected cells. The c-jun gene was induced significantly (data not shown). Northern blot analysis verified the trends in gene expression level as observed by array analysis (Figure 3a ). Next, we analysed the expression level of c-Jun and phospho-c-Jun in 293T and MCF-7 cells overexpressing Mayven. As shown, overexpression of Mayven induced both c-Jun protein expression ( Figure 3b ) and c-Jun activation ( Figure 3c ).
Mayven induces JNK activity
To examine the molecular mechanisms by which Mayven induced c-Jun, we investigated the MAPKs. Cultured 293T cells and human MCF-7 breast cancer cells were transfected with GFP-vector or GFP-Mayven. Cells transfected with GFP-Mayven showed clear activation of terminal kinase (JNK) as detected by phospho-JNK protein ( Figure 4 ). These results indicate that induction of c-Jun by Mayven is mediated via the activation of JNK.
The BTB/POZ domain is required for the induction of c-Jun by Mayven To identify which domain of Mayven is required for the induction of c-Jun, we transfected GFP-vector, GFP-Mayven, the GFP-Mayven BTB/ POZ domain and the GFP-Mayven Kelch domain into MCF-7 cells. Northern blot analysis demonstrated that only GFP-Mayven and the GFP-Mayven BTB/POZ domain induced c-Jun expression, while the Kelch domain had no effect ( Figure 5a ). Western blot analysis using c-Jun and phospho-c-Jun antibodies demonstrated the activation of c-Jun (Figure 5b ), indicating that the BTB/POZ domain and not the Kelch domain is required for the induction of c-Jun by Mayven.
Analysis of c-Jun and cyclin D1 expression in MCF-7 cells infected by sense and antisense retroviral Mayven recombinant viruses
The proliferation of MCF-7 cells is determined by cyclin D1 abundance (Zwijsen et al., 1996) . Moreover, AP-1 regulation of cellular proliferation involves the cyclin D1 gene (Albanese et al., 1995) . To examine if Mayven affects cyclin D1 expression, MCF-7 cells were transduced with the retrovirus control vector (pMIG-W), Mayven sense (pMIG-W-Mayven) or with antisense Mayven recombinant virus (pMIG-W-Mayven-AS). To purify the positive transduced cells, cell sorting was 
Mayven induces AP-1 transcriptional activity
Mayven strongly induced AP-1 luciferase reporter gene (JC6) activity in MCF-7 cells (Figure 7a ), but failed to induce AP-1 mutant reporter gene (JTX) activity in the cells (Figure 7a ). As shown in Figure 7b , the BTB/POZ domain was required for induction of AP-1 activity, while the Kelch domain failed to induce AP-1 activity.
Mayven induces cyclin D1 transcriptional activity
Next, we examined cyclin D1 promoter activity and its modulation by Mayven. Luciferase reporter constructs containing the full-length (À1745CD1) and various deletions or mutants (À963CD1, À963CD1/AP1, À163CD1 and À66CD1) of the promoter region were used for these studies. Mayven induced cyclin D1 promoter activity in a c-Jun/AP-1-dependent manner Figure 8a ). The full-length promoter reporter construct À1745CD1 and the deletion construct À963CD1 showed a maximal 9-10-fold activation. The À963CD1/AP-1 mutant reporter was not induced, indicating that the AP-1 site is required for the activation by Mayven. For the truncated reporter constructs À163CD1 and À66CD1, there was no activation, confirming the importance of the cyclin D1 promoter region containing the AP-1 site. Furthermore, the BTB/POZ domain of Mayven was found to be involved in this induction (Figure 8b ), while the Kelch domain was not required for AP-1 induction.
Mayven promoted cell cycle progression from the G1 to S phase
Since Mayven affected the expression and activities of both c-Jun and cyclin D1, which are involved in cell cycle progression, we examined the effects of Mayven expression on cell cycle progression from the G1 to S phase, using cell cycle analysis and BrdU incorporation assays. Mayven promoted cell cycle progression from the G1 to S phase ( Figure 9A ). In all, 43% of the MCF-7 cells were observed to be in the G0-G1 phase of the cell cycle (panel a). When cells were transfected with Mayven, a significant number (68%) were found in the S phase and less cells (26%) were observed in the G0-G1 phase (panel b), as compared to the empty vectortransfected cells. The BTB/POZ domain of Mayven promoted cell cycle progression from the G1 to S phase ( Figure 9A , compare panels a and c), similar to that observed with the full-length Mayven. No effects on cell cycle progression were observed with the Kelch domain ( Figure 9A, compare panels a and d) . These data were also confirmed by a BrdU incorporation assay ( Figure 9B ). Thus, Mayven promotes proliferation of breast cancer cells via upregulation of c-Jun, leading to modulation of JNK, and resulting in activation of cyclin D1 and cell cycle progression.
Discussion
In this study, we have demonstrated that Mayven is abundantly expressed and is broadly diffuse in breast cancers. In addition, we have shown that Mayven induced c-Jun expression and cyclin D1 promoter activity, and promoted cell cycle progression from the G1 to S phase in breast cancer cells. These results demonstrate for the first time that Mayven may play an important role in the etiology of breast cancer by upregulating c-Jun expression, which induces the upregulation of cyclin D1 promoter activity (see Figure 10 for a schematic presentation).
Mayven is a BTB/POZ domain-and kelch repeatscontaining protein. The BTB/POZ domain is an evolutionarily conserved region of about 115 amino acids present in a family of zinc-finger transcription factors as well as in a number of actin-binding and poxvirus proteins (Zollman et al., 1994; Dhordain et al., 2000) . In humans, some BTB/POZ domain transcription factors have been implicated in a number of cancers. These factors include BCL-6 (Whitmarsh et al., 1995; Chen et al., 1998) , PLZF (Chen et al., 1993; Dong et al., 1996) and APM-1 (Reuter et al., 1998) . The BTB/POZ domain provides a protein-protein interaction interface implicated in transcription activation (Deweindt et al., 1995; Chang et al., 1996; Seyfert et al., 1996; Kaplan and Calame, 1997) . Here, we demonstrate that Mayven, a new member of the BTB/POZ domain family, activated (Bohmann et al., 1987; Angel et al., 1988) . The transcription factor, c-Jun, forms dimeric complexes with high-affinity sequence-specific DNA-binding activity and regulates gene expression and cell function. c-Jun and its dimerization partners are regulated by extracellular stimuli, such as peptide growth factors, proinflammatory cytokines, oxidative and other forms of cellular stress, and UV irradiation (Hill et al., 1993) . c-Jun is expressed in human breast cancer cells and is activated by a variety of important growth factors such as EGF, heregulin, IGFs and estrogen (Ritke et al., 1994; Schmid et al., 1994; Szabo et al., 1996; . Interestingly, Mayven was found to upregulate c-Jun expression, suggesting the potential role of Mayven as an important cellular regulator of this pathway.
Little is known about the link between the BTB/POZ and Kelch domains and the AP-1 transcription factor. Krp1 (kelch-related protein 1) is a target of AP-1 activity. The Krp1 protein contains an N-terminal BTB/ POZ domain and C-terminal kelch repeats. Krp1 was isolated based on its upregulation upon transformation of 208F cells with v-fos and v-ras (Spence et al., 2000) . It colocalizes with F-actin in a dynamic membrane rufflelike structure, which forms looping conformations at the tips of pseudopodia in FBR cells. So far, Krp1 is the only BTB/POZ domain-and Kelch domain-containing protein that is known to be involved in AP-1 activation. Our data showing that Mayven targets c-Jun/AP-1 are novel in this aspect.
Some BTB/POZ domain-and Kelch domain-containing proteins play an important role in cell cycle regulation. As a transcription repressor, the BCL-6 proto-oncogene encodes a BTB/POZ domain at its N-terminal region and a zinc-finger domain at its C-terminal region (Deweindt et al., 1995; Chen et al., 1998) . Overexpression of BCL-6 induces apoptosis in CV-1 and HeLa cells, and this induction is preceded by downregulation of the apoptosis repressors BcL-2 and BcL-X(L). Inactivation by acetylation of BCL-6 leads to cell cycle arrest and apoptosis in B-cell lymphoma cells. PLZF is another BTB/POZ domain-containing protein that binds to FANCC and is localized in the nuclear compartment. Overexpression of PLZF induces G1phase arrest followed by apoptosis (Deweindt et al., 1995) . In humans, some BTB/POZ domain-containing proteins have been implicated in a number of cancers. These proteins include BCL-6 (Chang et al., 1996) , PLZF (Deweindt et al., 1995; Dong et al., 1996; Dhordain et al., 2000) , APM-1 (Reuter et al., 1998) , HIC-1 (hypermethylated in cancer) and NRP/B (Avraham et al., 2002) . Among these proteins, BCL-6 is associated with B-cell non-Hodgkin's lymphoma, and PLZF is associated with acute promyelocytic leukemia (APL). HIC-1 is a candidate tumor suppressor gene, which is frequently hypermethylated in human tumors, while NRP/B is a neuronal nuclear matrix protein (containing a BTB/POZ domain and kelch repeats) that is involved in brain tumor development and contributes to colorectal carcinogenesis (Avraham et al., 2002; Liang et al., 2004) . Based on the data presented here, Mayven -via its BTB/POZ domain -promotes cell cycle progression in breast cancer cells by upregulation of c-Jun expression leading to cyclin D1 activation.
AP-1 activity is indispensable for a variety of critical cellular functions. AP-1 not only mediates cellular responses to environmental stimuli, but also exerts a specific role during the cell cycle. It is noteworthy that numerous genes coding for components of both the cell cycle machinery (cyclins, cdks, etc.) and the DNA synthesis apparatus (PCNA, thymidine kinase, etc.) , 1990) . Cyclin D1 is a prototype of such a gene that may directly link AP-1 to cell cycle progression; it is implicated in G1 progression and can be induced efficiently by treatments that increase AP-1 activity, for example, mitogenic stimulation, ras transformation and ectopic c-Jun expression (Brown et al., 1998) . The downstream target of the c-jun gene, cyclin D1, is overexpressed in many human cancers (Toyoshima and Hunter, 1994) , including B50% of breast cancers. Inhibition of cyclin D1 expression leads to growth arrest of cancer cells (Schrump et al., 1996) . Cyclin D1 antisense treatment blocks mammary tumor growth in vivo (Lee et al., 2000) and cyclin D1 knockout (Fantl et al., 1995; Yu et al., 2001) . In this study, Mayven induced c-Jun protein expression and increased the ability of c-Jun to activate the cyclin D1 promoter through the c-Jun/AP-1 complex and JNK pathways. Thus, Mayven is a possible new potent regulator of c-Jun and cyclin D1 activity.
In summary, our results show that Mayven significantly induces c-Jun expression and activity, leading to the activation of cyclin D1 through JNK pathways and to cell cycle progression. These findings elucidate a new role of the BTB/POZ domain of Mayven as a regulator of c-Jun and cyclin D1.
Materials and methods
Reagents [g-32 P]dCTP and [g-32 P]dATP were purchased from NEN. c-Jun and phosphorylated c-Jun antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). JNK/SAPK antibodies, and antibodies against the respective phosphorylated proteins were purchased from New England BioLabs. BrdU antibody was purchased from BD Biosciences.
Cell cultures and transfection experiments All cell lines were obtained from the American Type Culture Collection and were grown in Dulbecco's modified Eagle's medium with 10% FCS, as described (Soltysik-Espanola et al., 1999) . The MDA-MB-231 human breast cancer cell line was maintained in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, penicillin/streptomycin (100 IU/ml) and 0.29 mg/ml L-glutamine. T47D and MCF-7 human breast cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI medium, 10% fetal bovine serum, 10 mg/ml insulin, penicillin/streptomycin (100 IU/ml) and L-glutamine (0.29 mg/ml). Cells were transfected with the indicated plasmids using Lipofectamine plus reagent (Invitrogen). After a 48-h transfection, cells were lysed in 600 ml of lysis buffer (50 mM Tris/HCl, pH 7.6, 1% Triton X-100, 150 mM NaCl, 0.1 mM EDTA, 10% glycerol and proteinase inhibitor mixture) and put on ice for 15 min. After centrifugation for 15 min at 41C, cell lysates were preincubated with protein G-Sepharose beads for 1 h at 41C. Total cell lysates were analysed by Western blotting.
Western blotting
Supernatant lysates were separated by SDS-polyacrylamide gel electrophoresis (12%) and transferred to polyvinylidene difluoride membranes for 15 h at 30 mV. Polyvinylidene difluoride membranes were processed as described previously (Soltysik-Espanola et al., 1999) .
Immunohistochemical staining
Immunohistochemical staining was performed with the Hostostain Kit (Aymed Lab, CA, USA), according to the protocol provided by the manufacturer. Briefly, paraffin-embedded tissues were treated for peroxidase quenching. Serum (100 ml) was added as a blocking solution, followed by incubation at room temperature for 10 min. The primary antibodies (normal rabbit serum or rabbit anti-Mayven antibodies) (Soltysik-Espanola et al., 1999) were added and incubated at room temperature for 30 min. The slides were washed five times with 1 Â PBS. Biotinylated secondary antibodies were added and incubated at room temperature for 20 min. The samples were washed and 100 ml of streptavidin-horseradish peroxidase conjugate was applied for 5 min. The color reactions were performed by adding DAB, the substrate for horseradish peroxidase.
Immunofluorescence microscopy Cells were plated on coverslips 2 days before each experiment at a concentration of 3 Â 10 4 -5 Â 10 4 /35-mm dish. Cells were fixed (by the addition of 3% formaldehyde) directly to the coverslips. The cells were rinsed extensively with PBS (pH 7.4), incubated for 1 h with PBS containing 2% BSA, 2% normal goat serum and 0.2% gelatin at room temperature to reduce the nonspecific binding, and then incubated with primary antibodies for 1 h at room temperature. After washing, the cells were incubated with secondary antibodies for 30 min at room temperature. Following cell labeling, the coverslips were mounted and viewed with a Zeiss fluorescent microscope, and then confocal analysis was performed with an inverted confocal microscope.
cDNA expression array analysis The Atlas cDNA expression array purchased from Clontech Laboratories (Palo Alto, CA, USA) was used for this experiment. This array contains 1200 human genes. Each cDNA fragment is 200-600 bp in length and has been amplified Induction of c-Jun by Mayven X Bu et al from a region of the mRNA that lacks the poly-A tail, repetitive elements or other highly homologous sequences. When the array membrane was hybridized with an a-32 P-labeled cDNA probe, the background level was sufficiently low to permit detection of mRNA present at only 10-20 copies per cell. Multiple housekeeping gene cDNAs were spotted on each array membrane as positive controls. cDNA expression arrays were performed following the manufacturer's guide (Clontech). Briefly, cells transfected with Mayven construct or control vector were collected and RNA was extracted with Trizol reagent. Probe synthesis was performed by reverse transcribing 1 mg of each RNA population using cDNA synthesis primer mix, and the probe was then labeled with [g-32 P]dATP. The probes were purified by column chromatography. The radioactivity was tested by scintillation counting. Each labeled probe mix was then hybridized to the array membranes. After a high-stringency wash, the hybridization pattern was analysed by autoradiography and quantified by phosphorimaging. The results were analysed with AtlasImage software, and normalization was performed based on the expression level of the housekeeping genes.
Northern blot analysis Total cellular RNA was extracted by Trizol reagent according to the manufacturer's instructions (GIBCO). For RNA analysis, 20 mg of total RNA was electrophoresed in a 1.2% agaroseformaldehyde gel, and transferred to nitrocellulose membrane (Schleicher & Schuell Inc., Keene, NH, USA). Membranes were prehybridized at 421C in 50% formamide, 1 Â Denhardt's solution, 5 Â SSC (1 Â SSC ¼ 150 mM NaCl, 15 mM sodium citrate) and 50 mg/ml denatured and fragmented salmon sperm DNA. Hybridization was performed at 421C in prehybridization solution containing 10% dextran sulfate, with c-jun cDNA probes. For posthybridization, blots were washed twice and analysed as described previously (Soltysik-Espanola et al., 1999) .
Flow cytometric analysis Cells were trypsinized and collected by centrifugation at 2000 r.p.m. for 5 min. The cell pellets were then resuspended in 1 ml portions of PBS, fixed in 70% ice-cold ethanol and incubated at 41C overnight. Fixed cells were centrifuged, washed once in PBS and then resuspended in PBS containing 50 mg of propidium iodide (Sigma) per ml and 100 mg of DNasefree RNase A (Boehringer Mannheim) per ml. The cell suspension was incubated for 30 min at 371C, protected against light and then analysed with a FACScan flow cytometer. The propidium iodide-stained DNA content of each cell was used as the parameter for the cell cycle profile.
AP-1 and cyclin D1 promoter assays For the reporter assays, the appropriate reporter gene (see figure legends for details) was transfected into 293T cells and MCF-7 cells at 60% confluence using LipofectAMINE reagent (Invitrogen) as indicated. Each plate was transfected with 5 mg of the appropriate luciferase reporter construct, and 2 mg of pA2-PRL Luc and CMV-PRL, which served to normalize the cells for viability and transfection efficiency. At 24 h after transfection, the cell medium was changed and cells were further incubated for an additional 24 h. Cell extracts were prepared by lysing the cells with three sequential freeze-thaw cycles in buffer containing 100 mM potassium phosphate, pH 7.8, and 10 mM dithiothreitol. Vigorous vortexing was used to enhance cell lysis. Unlysed cells and insoluble material were pelleted at 10 000 r.p.m. for 10 min at 41C. The supernatant volume was measured, and aliquots of the supernatant were used in the subsequent luciferase assays. The luciferase assay mixture contained 100 mM KPO 4 , pH 7.8, 1 mM dithiothreitol, 3.7 mM MgSO 4 , 530 mM ATP and 470 mM luciferin plus 20 ml of cell extract in a final volume of 100 ml. Luciferin was added just before measuring the light units, which were assessed in duplicate during the first 40 s of the reaction at 251C in a luminometer. Luciferase light units were normalized relative to the activity of CMV-PRL. The control value was then set at 1 and the data were expressed as the fold stimulation relative to the control. The reporter gene constructs used were the following: pJLuc, which contains À225 to þ 150 of the c-Jun enhancer/promoter upstream of the basal promoterluciferase gene pGL2; pLC6, which contains À225 to þ 150 of the c-Jun enhancer/promoter upstream of the basal promoter-luciferase gene (this construct contains the same rare regulatory elements as does pJLuc except that a later generation luciferase reporter gene was used as the backbone -pGL2); pJTX (same as the wild-type pJC6 apart from a point mutation in the AP-1-binding site). The cyclin D1 promoter constructs, in which the human cyclin D1 promoter was subcloned into the vector pA3Luc, were described previously (Lee et al., 2000; Liu et al., 2002) .
Retroviral-mediated transduction of MCF-7 cells with sense and antisense Mayven Sense and antisense cDNAs of human Mayven were cloned into an IRES-GFP-containing bicistronic retrovirus vector (pMIG-W). The resultant retroviral plasmids were cotransfected with CMV-gag-pol and vsvg (Env) plasmids into 293T cells using Lipofectamine (Life Technologies Inc.) to produce viral supernatant. The titer of the pMIG-W, pMIG-W-Mayven (sense) and pMIG-W-Mayven-AS (antisense) viral supernatants generated by the transfected 293T cells was 1 Â 10 6 , 4 Â 10 5 and 3 Â 10 5 IU/ml, respectively. The retroviral supernatants were used to transduce the MCF-7 breast cancer cells. The GFPexpressing cells were isolated by a cell sorter under sterile conditions. The selected positive cells were recultured for 36 h, sorted by FACS and then were collected and analysed further, as indicated.
Statistics Statistical analysis was performed by using the Student's t-test. Data are expressed as the mean7s.e.
